# EP0057 in Combination With Olaparib in Advanced Ovarian Cancer

> **NCT04669002** · PHASE2 · COMPLETED · sponsor: **Ellipses Pharma** · enrollment: 34 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** EP0057
- **DRUG:** Olaparib tablets

## Key facts

- **NCT ID:** NCT04669002
- **Lead sponsor:** Ellipses Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-14
- **Primary completion:** 2023-02-17
- **Final completion:** 2023-05-05
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04669002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04669002, "EP0057 in Combination With Olaparib in Advanced Ovarian Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04669002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*